Global Exosome Diagnostics and Therapeutics

Exosome Diagnostics and Therapeutics Comprehensive Study by Type (Diagnostic, Therapeutic), Application (Cancer Institute, Hospital, Diagnostic Center, Others), Components (Instrument, Reagent, Software), Exosome Isolation Methods (Differential Centrifugation, Charge Neutralization, Gel-filtration/size-Exclusion Chromatography, Stirred Ultrafiltration, Nanoplasmon-enhanced Scattering, Others) Players and Region - Global Market Outlook to 2030

Exosome Diagnostics and Therapeutics Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 21%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Exosome Diagnostics and Therapeutics
Exosome Diagnostics and therapeutics involve the diagnosis, monitoring, and treatment of problems linked with exosomes presence in the body, exosome are nano-sized enclosed vesicles that include proteins like RNAs and microRNAs. With the rising number of neurodegenerative and cancer-related diseases, the exosome diagnostics and therapeutics market is expected to increase during the forecasted period. The exosome diagnostics and therapeutics methods include differential centrifugation, charge neutralization, gel-filtration/size-exclusion chromatography, stirred ultrafiltration, nanoplasmonic-enhanced scattering, and others.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR21.0%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Exosome Diagnostics and Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Aethlon Medical (Exosome Sciences) (United States), Thermo Fisher Scientific (United States), Exosome Diagnostics Inc. (Bio-Techne Corporation) (United States), NanoSomiX, Inc. (United States), Codiak BioSciences (United States), Spectris plc (Malvern Instruments) (United Kingdom), System Biosciences, LLC (United States), Capricor Therapeutics (United States), Evox Therapeutics (United Kingdom) and Sarepta Therapeutics, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Exosome Diagnostics and Therapeutics market by Type (Diagnostic and Therapeutic), Application (Cancer Institute, Hospital, Diagnostic Center and Others) and Region.



On the basis of geography, the market of Exosome Diagnostics and Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Components, the sub-segment i.e. Instrument will boost the Exosome Diagnostics and Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Exosome Isolation Methods, the sub-segment i.e. Differential Centrifugation will boost the Exosome Diagnostics and Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Introduction of Biomedical Analysis in Exosome Diagnostics and Therapeutics

Market Growth Drivers:
Growing Prevalence of Neurodegenerative Diseases in People and Rising Lung Cancer and Other Types of Cancer Requires Diagnosis and Therapeutics

Challenges:
Technical Clinical Problem Involved with the Exosome Diagnostics and Therapeutics

Restraints:
Stringent Regulatory Guidelines Associated with Exosome Diagnostics and Therapeutics

Opportunities:
Continuous Research and Development in the Exosome Diagnostics and Therapeutics and Surging Healthcare Spendings will boost the Exosome Diagnostics and Therapeutics market

Market Leaders and their expansionary development strategies
In September 2023, Emisphere Technologies, a clinical-stage biopharmaceutical company, acquired Exo Therapeutics, a developer of exosome-based cancer therapies. This acquisition strengthens Emisphere's oncology pipeline and expertise in exosome technology.
In September 2023, Codiak Biosciences unveiled its proprietary exosome engineering platform, capable of manufacturing exosomes with specific therapeutic properties. This platform has the potential to revolutionize the development of exosome-based therapies.


Key Target Audience
Exosome Diagnostics and Therapeutics Service Providers, Exosome Diagnostics and Therapeutics Industry Association, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Diagnostic
  • Therapeutic
By Application
  • Cancer Institute
  • Hospital
  • Diagnostic Center
  • Others
By Components
  • Instrument
  • Reagent
  • Software

By Exosome Isolation Methods
  • Differential Centrifugation
  • Charge Neutralization
  • Gel-filtration/size-Exclusion Chromatography
  • Stirred Ultrafiltration
  • Nanoplasmon-enhanced Scattering
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Neurodegenerative Diseases in People
      • 3.2.2. Rising Lung Cancer and Other Types of Cancer Requires Diagnosis and Therapeutics
    • 3.3. Market Challenges
      • 3.3.1. Technical Clinical Problem Involved with the Exosome Diagnostics and Therapeutics
    • 3.4. Market Trends
      • 3.4.1. Introduction of Biomedical Analysis in Exosome Diagnostics and Therapeutics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Exosome Diagnostics and Therapeutics, by Type, Application, Components, Exosome Isolation Methods and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Exosome Diagnostics and Therapeutics (Value)
      • 5.2.1. Global Exosome Diagnostics and Therapeutics by: Type (Value)
        • 5.2.1.1. Diagnostic
        • 5.2.1.2. Therapeutic
      • 5.2.2. Global Exosome Diagnostics and Therapeutics by: Application (Value)
        • 5.2.2.1. Cancer Institute
        • 5.2.2.2. Hospital
        • 5.2.2.3. Diagnostic Center
        • 5.2.2.4. Others
      • 5.2.3. Global Exosome Diagnostics and Therapeutics by: Components (Value)
        • 5.2.3.1. Instrument
        • 5.2.3.2. Reagent
        • 5.2.3.3. Software
      • 5.2.4. Global Exosome Diagnostics and Therapeutics by: Exosome Isolation Methods (Value)
        • 5.2.4.1. Differential Centrifugation
        • 5.2.4.2. Charge Neutralization
        • 5.2.4.3. Gel-filtration/size-Exclusion Chromatography
        • 5.2.4.4. Stirred Ultrafiltration
        • 5.2.4.5. Nanoplasmon-enhanced Scattering
        • 5.2.4.6. Others
      • 5.2.5. Global Exosome Diagnostics and Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Exosome Diagnostics and Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Aethlon Medical (Exosome Sciences) (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Exosome Diagnostics Inc. (Bio-Techne Corporation) (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. NanoSomiX, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Codiak BioSciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Spectris plc (Malvern Instruments) (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. System Biosciences, LLC (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Capricor Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Evox Therapeutics (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sarepta Therapeutics, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Exosome Diagnostics and Therapeutics Sale, by Type, Application, Components, Exosome Isolation Methods and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Exosome Diagnostics and Therapeutics (Value)
      • 7.2.1. Global Exosome Diagnostics and Therapeutics by: Type (Value)
        • 7.2.1.1. Diagnostic
        • 7.2.1.2. Therapeutic
      • 7.2.2. Global Exosome Diagnostics and Therapeutics by: Application (Value)
        • 7.2.2.1. Cancer Institute
        • 7.2.2.2. Hospital
        • 7.2.2.3. Diagnostic Center
        • 7.2.2.4. Others
      • 7.2.3. Global Exosome Diagnostics and Therapeutics by: Components (Value)
        • 7.2.3.1. Instrument
        • 7.2.3.2. Reagent
        • 7.2.3.3. Software
      • 7.2.4. Global Exosome Diagnostics and Therapeutics by: Exosome Isolation Methods (Value)
        • 7.2.4.1. Differential Centrifugation
        • 7.2.4.2. Charge Neutralization
        • 7.2.4.3. Gel-filtration/size-Exclusion Chromatography
        • 7.2.4.4. Stirred Ultrafiltration
        • 7.2.4.5. Nanoplasmon-enhanced Scattering
        • 7.2.4.6. Others
      • 7.2.5. Global Exosome Diagnostics and Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Exosome Diagnostics and Therapeutics: by Type(USD Million)
  • Table 2. Exosome Diagnostics and Therapeutics Diagnostic , by Region USD Million (2018-2023)
  • Table 3. Exosome Diagnostics and Therapeutics Therapeutic , by Region USD Million (2018-2023)
  • Table 4. Exosome Diagnostics and Therapeutics: by Application(USD Million)
  • Table 5. Exosome Diagnostics and Therapeutics Cancer Institute , by Region USD Million (2018-2023)
  • Table 6. Exosome Diagnostics and Therapeutics Hospital , by Region USD Million (2018-2023)
  • Table 7. Exosome Diagnostics and Therapeutics Diagnostic Center , by Region USD Million (2018-2023)
  • Table 8. Exosome Diagnostics and Therapeutics Others , by Region USD Million (2018-2023)
  • Table 9. Exosome Diagnostics and Therapeutics: by Components(USD Million)
  • Table 10. Exosome Diagnostics and Therapeutics Instrument , by Region USD Million (2018-2023)
  • Table 11. Exosome Diagnostics and Therapeutics Reagent , by Region USD Million (2018-2023)
  • Table 12. Exosome Diagnostics and Therapeutics Software , by Region USD Million (2018-2023)
  • Table 13. Exosome Diagnostics and Therapeutics: by Exosome Isolation Methods(USD Million)
  • Table 14. Exosome Diagnostics and Therapeutics Differential Centrifugation , by Region USD Million (2018-2023)
  • Table 15. Exosome Diagnostics and Therapeutics Charge Neutralization , by Region USD Million (2018-2023)
  • Table 16. Exosome Diagnostics and Therapeutics Gel-filtration/size-Exclusion Chromatography , by Region USD Million (2018-2023)
  • Table 17. Exosome Diagnostics and Therapeutics Stirred Ultrafiltration , by Region USD Million (2018-2023)
  • Table 18. Exosome Diagnostics and Therapeutics Nanoplasmon-enhanced Scattering , by Region USD Million (2018-2023)
  • Table 19. Exosome Diagnostics and Therapeutics Others , by Region USD Million (2018-2023)
  • Table 20. South America Exosome Diagnostics and Therapeutics, by Country USD Million (2018-2023)
  • Table 21. South America Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 22. South America Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 23. South America Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 24. South America Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 25. Brazil Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 26. Brazil Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 27. Brazil Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 28. Brazil Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 29. Argentina Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 30. Argentina Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 31. Argentina Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 32. Argentina Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 33. Rest of South America Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 34. Rest of South America Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 35. Rest of South America Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 36. Rest of South America Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 37. Asia Pacific Exosome Diagnostics and Therapeutics, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 39. Asia Pacific Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 40. Asia Pacific Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 41. Asia Pacific Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 42. China Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 43. China Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 44. China Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 45. China Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 46. Japan Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 47. Japan Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 48. Japan Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 49. Japan Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 50. India Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 51. India Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 52. India Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 53. India Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 54. South Korea Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 55. South Korea Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 56. South Korea Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 57. South Korea Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 58. Taiwan Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 59. Taiwan Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 60. Taiwan Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 61. Taiwan Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 62. Australia Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 63. Australia Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 64. Australia Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 65. Australia Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 70. Europe Exosome Diagnostics and Therapeutics, by Country USD Million (2018-2023)
  • Table 71. Europe Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 72. Europe Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 73. Europe Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 74. Europe Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 75. Germany Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 76. Germany Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 77. Germany Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 78. Germany Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 79. France Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 80. France Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 81. France Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 82. France Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 83. Italy Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 84. Italy Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 85. Italy Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 86. Italy Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 87. United Kingdom Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 88. United Kingdom Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 89. United Kingdom Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 90. United Kingdom Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 91. Netherlands Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 92. Netherlands Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 93. Netherlands Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 94. Netherlands Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 95. Rest of Europe Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 96. Rest of Europe Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 97. Rest of Europe Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 98. Rest of Europe Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 99. MEA Exosome Diagnostics and Therapeutics, by Country USD Million (2018-2023)
  • Table 100. MEA Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 101. MEA Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 102. MEA Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 103. MEA Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 104. Middle East Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 105. Middle East Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 106. Middle East Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 107. Middle East Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 108. Africa Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 109. Africa Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 110. Africa Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 111. Africa Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 112. North America Exosome Diagnostics and Therapeutics, by Country USD Million (2018-2023)
  • Table 113. North America Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 114. North America Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 115. North America Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 116. North America Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 117. United States Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 118. United States Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 119. United States Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 120. United States Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 121. Canada Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 122. Canada Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 123. Canada Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 124. Canada Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 125. Mexico Exosome Diagnostics and Therapeutics, by Type USD Million (2018-2023)
  • Table 126. Mexico Exosome Diagnostics and Therapeutics, by Application USD Million (2018-2023)
  • Table 127. Mexico Exosome Diagnostics and Therapeutics, by Components USD Million (2018-2023)
  • Table 128. Mexico Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2018-2023)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Exosome Diagnostics and Therapeutics: by Type(USD Million)
  • Table 140. Exosome Diagnostics and Therapeutics Diagnostic , by Region USD Million (2025-2030)
  • Table 141. Exosome Diagnostics and Therapeutics Therapeutic , by Region USD Million (2025-2030)
  • Table 142. Exosome Diagnostics and Therapeutics: by Application(USD Million)
  • Table 143. Exosome Diagnostics and Therapeutics Cancer Institute , by Region USD Million (2025-2030)
  • Table 144. Exosome Diagnostics and Therapeutics Hospital , by Region USD Million (2025-2030)
  • Table 145. Exosome Diagnostics and Therapeutics Diagnostic Center , by Region USD Million (2025-2030)
  • Table 146. Exosome Diagnostics and Therapeutics Others , by Region USD Million (2025-2030)
  • Table 147. Exosome Diagnostics and Therapeutics: by Components(USD Million)
  • Table 148. Exosome Diagnostics and Therapeutics Instrument , by Region USD Million (2025-2030)
  • Table 149. Exosome Diagnostics and Therapeutics Reagent , by Region USD Million (2025-2030)
  • Table 150. Exosome Diagnostics and Therapeutics Software , by Region USD Million (2025-2030)
  • Table 151. Exosome Diagnostics and Therapeutics: by Exosome Isolation Methods(USD Million)
  • Table 152. Exosome Diagnostics and Therapeutics Differential Centrifugation , by Region USD Million (2025-2030)
  • Table 153. Exosome Diagnostics and Therapeutics Charge Neutralization , by Region USD Million (2025-2030)
  • Table 154. Exosome Diagnostics and Therapeutics Gel-filtration/size-Exclusion Chromatography , by Region USD Million (2025-2030)
  • Table 155. Exosome Diagnostics and Therapeutics Stirred Ultrafiltration , by Region USD Million (2025-2030)
  • Table 156. Exosome Diagnostics and Therapeutics Nanoplasmon-enhanced Scattering , by Region USD Million (2025-2030)
  • Table 157. Exosome Diagnostics and Therapeutics Others , by Region USD Million (2025-2030)
  • Table 158. South America Exosome Diagnostics and Therapeutics, by Country USD Million (2025-2030)
  • Table 159. South America Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 160. South America Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 161. South America Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 162. South America Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 163. Brazil Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 164. Brazil Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 165. Brazil Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 166. Brazil Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 167. Argentina Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 168. Argentina Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 169. Argentina Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 170. Argentina Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 171. Rest of South America Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 172. Rest of South America Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 173. Rest of South America Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 174. Rest of South America Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 175. Asia Pacific Exosome Diagnostics and Therapeutics, by Country USD Million (2025-2030)
  • Table 176. Asia Pacific Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 177. Asia Pacific Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 178. Asia Pacific Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 179. Asia Pacific Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 180. China Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 181. China Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 182. China Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 183. China Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 184. Japan Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 185. Japan Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 186. Japan Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 187. Japan Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 188. India Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 189. India Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 190. India Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 191. India Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 192. South Korea Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 193. South Korea Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 194. South Korea Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 195. South Korea Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 196. Taiwan Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 197. Taiwan Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 198. Taiwan Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 199. Taiwan Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 200. Australia Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 201. Australia Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 202. Australia Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 203. Australia Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 208. Europe Exosome Diagnostics and Therapeutics, by Country USD Million (2025-2030)
  • Table 209. Europe Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 210. Europe Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 211. Europe Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 212. Europe Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 213. Germany Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 214. Germany Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 215. Germany Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 216. Germany Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 217. France Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 218. France Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 219. France Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 220. France Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 221. Italy Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 222. Italy Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 223. Italy Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 224. Italy Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 225. United Kingdom Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 226. United Kingdom Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 227. United Kingdom Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 228. United Kingdom Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 229. Netherlands Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 230. Netherlands Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 231. Netherlands Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 232. Netherlands Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 233. Rest of Europe Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 234. Rest of Europe Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 235. Rest of Europe Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 236. Rest of Europe Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 237. MEA Exosome Diagnostics and Therapeutics, by Country USD Million (2025-2030)
  • Table 238. MEA Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 239. MEA Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 240. MEA Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 241. MEA Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 242. Middle East Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 243. Middle East Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 244. Middle East Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 245. Middle East Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 246. Africa Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 247. Africa Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 248. Africa Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 249. Africa Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 250. North America Exosome Diagnostics and Therapeutics, by Country USD Million (2025-2030)
  • Table 251. North America Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 252. North America Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 253. North America Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 254. North America Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 255. United States Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 256. United States Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 257. United States Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 258. United States Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 259. Canada Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 260. Canada Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 261. Canada Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 262. Canada Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 263. Mexico Exosome Diagnostics and Therapeutics, by Type USD Million (2025-2030)
  • Table 264. Mexico Exosome Diagnostics and Therapeutics, by Application USD Million (2025-2030)
  • Table 265. Mexico Exosome Diagnostics and Therapeutics, by Components USD Million (2025-2030)
  • Table 266. Mexico Exosome Diagnostics and Therapeutics, by Exosome Isolation Methods USD Million (2025-2030)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Exosome Diagnostics and Therapeutics: by Type USD Million (2018-2023)
  • Figure 5. Global Exosome Diagnostics and Therapeutics: by Application USD Million (2018-2023)
  • Figure 6. Global Exosome Diagnostics and Therapeutics: by Components USD Million (2018-2023)
  • Figure 7. Global Exosome Diagnostics and Therapeutics: by Exosome Isolation Methods USD Million (2018-2023)
  • Figure 8. South America Exosome Diagnostics and Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Exosome Diagnostics and Therapeutics Share (%), by Country
  • Figure 10. Europe Exosome Diagnostics and Therapeutics Share (%), by Country
  • Figure 11. MEA Exosome Diagnostics and Therapeutics Share (%), by Country
  • Figure 12. North America Exosome Diagnostics and Therapeutics Share (%), by Country
  • Figure 13. Global Exosome Diagnostics and Therapeutics share by Players 2023 (%)
  • Figure 14. Global Exosome Diagnostics and Therapeutics share by Players (Top 3) 2023(%)
  • Figure 15. Global Exosome Diagnostics and Therapeutics share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Aethlon Medical (Exosome Sciences) (United States) Revenue, Net Income and Gross profit
  • Figure 18. Aethlon Medical (Exosome Sciences) (United States) Revenue: by Geography 2023
  • Figure 19. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 20. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 21. Exosome Diagnostics Inc. (Bio-Techne Corporation) (United States) Revenue, Net Income and Gross profit
  • Figure 22. Exosome Diagnostics Inc. (Bio-Techne Corporation) (United States) Revenue: by Geography 2023
  • Figure 23. NanoSomiX, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. NanoSomiX, Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Codiak BioSciences (United States) Revenue, Net Income and Gross profit
  • Figure 26. Codiak BioSciences (United States) Revenue: by Geography 2023
  • Figure 27. Spectris plc (Malvern Instruments) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Spectris plc (Malvern Instruments) (United Kingdom) Revenue: by Geography 2023
  • Figure 29. System Biosciences, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 30. System Biosciences, LLC (United States) Revenue: by Geography 2023
  • Figure 31. Capricor Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 32. Capricor Therapeutics (United States) Revenue: by Geography 2023
  • Figure 33. Evox Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Evox Therapeutics (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Sarepta Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Sarepta Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Global Exosome Diagnostics and Therapeutics: by Type USD Million (2025-2030)
  • Figure 38. Global Exosome Diagnostics and Therapeutics: by Application USD Million (2025-2030)
  • Figure 39. Global Exosome Diagnostics and Therapeutics: by Components USD Million (2025-2030)
  • Figure 40. Global Exosome Diagnostics and Therapeutics: by Exosome Isolation Methods USD Million (2025-2030)
  • Figure 41. South America Exosome Diagnostics and Therapeutics Share (%), by Country
  • Figure 42. Asia Pacific Exosome Diagnostics and Therapeutics Share (%), by Country
  • Figure 43. Europe Exosome Diagnostics and Therapeutics Share (%), by Country
  • Figure 44. MEA Exosome Diagnostics and Therapeutics Share (%), by Country
  • Figure 45. North America Exosome Diagnostics and Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Aethlon Medical (Exosome Sciences) (United States)
  • Thermo Fisher Scientific (United States)
  • Exosome Diagnostics Inc. (Bio-Techne Corporation) (United States)
  • NanoSomiX, Inc. (United States)
  • Codiak BioSciences (United States)
  • Spectris plc (Malvern Instruments) (United Kingdom)
  • System Biosciences, LLC (United States)
  • Capricor Therapeutics (United States)
  • Evox Therapeutics (United Kingdom)
  • Sarepta Therapeutics, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 205 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Exosome Diagnostics and Therapeutics Quantitative research analysis
Global Exosome Diagnostics and Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Aethlon Medical (Exosome Sciences) (United States), Thermo Fisher Scientific (United States), Exosome Diagnostics Inc. (Bio-Techne Corporation) (United States), NanoSomiX, Inc. (United States), Codiak BioSciences (United States), Spectris plc (Malvern Instruments) (United Kingdom), System Biosciences, LLC (United States), Capricor Therapeutics (United States), Evox Therapeutics (United Kingdom) and Sarepta Therapeutics, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Introduction of Biomedical Analysis in Exosome Diagnostics and Therapeutics" is seen as one of major influencing trends for Exosome Diagnostics and Therapeutics Market during projected period 2023-2030.
The Exosome Diagnostics and Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Exosome Diagnostics and Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Gonorrhea Testing Comprehensive Study by Test (Nucleic Acid Amplification (NAA), Gram Stain, Enzyme-linked immunosorbent assay (ELISA), Gonorrhea Culture, Rapid test), Sample (Blood, Lymph fluid, Uri...
$ 3450
Microwave Therapeutic Instruments Comprehensive Study by Type (Monopolar, Bipolar), Application (Arthritis, Back Pain, Fibromyalgia, Muscle Spasms, Myositis, Neuralgia, Sprains And Strains, Tenosynov...
$ 3650
Diagnostic Technology Comprehensive Study by Type (Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Microbiology, Hematology, Coagulation and Hemostasis, Urinalysis, Other IVD ...
$ 3750
Heart Failure Therapeutics - Comprehensive Study by Type (Diagnosis, Prognosis), Application (Hospital, Clinic, Medical Research Organization) Players and Region - Global Market Outlook to 2030
$ 3500
Oligodendroglioma Treatment Comprehensive Study by Treatment Type Names (Surgery, Radiotherapy, Chemotherapy), Type of Oligodendroglioma (Pure Oligodendroglioma, Mixed Oligodendroglioma), Grade Type ...
$ 3350
Cervical Cancer Comprehensive Study by Type (Squamous cell carcinoma, Adenocarcinoma), Application (Hospitals, Cancer Palliative care clinics, Diagnostic centers, Pharmacies), Drug Type (Avastin (Bev...
$ 3750